Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment
We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer’s Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretati...
Saved in:
| Published in: | Scientific reports Vol. 14; no. 1; pp. 11307 - 12 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
17-05-2024
Nature Publishing Group Nature Portfolio |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer’s Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1–40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP−) when they were A−, A+/T−/N−, or A+/T−/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP− patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn’s k = 0.50,
p
< 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology. |
|---|---|
| AbstractList | Abstract We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer’s Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1–40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP−) when they were A−, A+/T−/N−, or A+/T−/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP− patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn’s k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology. We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer’s Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1–40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP−) when they were A−, A+/T−/N−, or A+/T−/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP− patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn’s k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology. We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer's Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1-40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP-) when they were A-, A+/T-/N-, or A+/T-/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP- patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn's k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology.We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer's Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1-40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP-) when they were A-, A+/T-/N-, or A+/T-/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP- patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn's k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology. We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer’s Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1–40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP−) when they were A−, A+/T−/N−, or A+/T−/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP− patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn’s k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology. We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) patients carrying Alzheimer's Disease (AD) pathology from non-carriers; to propose a flowchart for the interpretation of the results of plasma p-tau181 and NfL. We included 43 SCD, 41 MCI and 21 AD-demented (AD-d) patients, who underwent plasma p-tau181 and NfL analysis. Twenty-eight SCD, 41 MCI and 21 AD-d patients underwent CSF biomarkers analysis (Aβ1-42, Aβ1-42/1-40, p-tau, t-tau) and were classified as carriers of AD pathology (AP+) it they were A+/T+ , or non-carriers (AP-) when they were A-, A+/T-/N-, or A+/T-/N+ according to the A/T(N) system. Plasma p-tau181 and NfL separately showed a good accuracy (AUC = 0.88), while the combined model (NfL + p-tau181) showed an excellent accuracy (AUC = 0.92) in discriminating AP+ from AP- patients. Plasma p-tau181 and NfL results were moderately concordant (Coehn's k = 0.50, p < 0.001). Based on a logistic regression model, we estimated the risk of AD pathology considering the two biomarkers: 10.91% if both p-tau181 and NfL were negative; 41.10 and 76.49% if only one biomarker was positive (respectively p-tau18 and NfL); 94.88% if both p-tau181 and NfL were positive. Considering the moderate concordance and the risk of presenting an underlying AD pathology according to the positivity of plasma p-tau181 and NfL, we proposed a flow chart to guide the combined use of plasma p-tau181 and NfL and the interpretation of biomarker results to detect AD pathology. |
| ArticleNumber | 11307 |
| Author | Crucitti, Chiara Ferrari, Camilla Sorbi, Sandro Ingannato, Assunta Bagnoli, Silvia Morinelli, Carmen Mazzeo, Salvatore Bessi, Valentina Giacomucci, Giulia Nacmias, Benedetta Emiliani, Filippo Padiglioni, Sonia Moschini, Valentina Notarelli, Antonella Galdo, Giulia Romano, Lucrezia Frigerio, Daniele |
| Author_xml | – sequence: 1 givenname: Giulia surname: Giacomucci fullname: Giacomucci, Giulia organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 2 givenname: Salvatore surname: Mazzeo fullname: Mazzeo, Salvatore organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Vita-Salute San Raffaele University, IRCCS Policlinico San Donato – sequence: 3 givenname: Assunta surname: Ingannato fullname: Ingannato, Assunta organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 4 givenname: Chiara surname: Crucitti fullname: Crucitti, Chiara organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 5 givenname: Silvia surname: Bagnoli fullname: Bagnoli, Silvia organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 6 givenname: Sonia surname: Padiglioni fullname: Padiglioni, Sonia organization: Regional Referral Centre for Relational Criticalities - Tuscany Region, University of Florence, Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi – sequence: 7 givenname: Lucrezia surname: Romano fullname: Romano, Lucrezia organization: University of Florence – sequence: 8 givenname: Giulia surname: Galdo fullname: Galdo, Giulia organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 9 givenname: Filippo surname: Emiliani fullname: Emiliani, Filippo organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 10 givenname: Daniele surname: Frigerio fullname: Frigerio, Daniele organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 11 givenname: Camilla surname: Ferrari fullname: Ferrari, Camilla organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence – sequence: 12 givenname: Valentina surname: Moschini fullname: Moschini, Valentina organization: SOD Neurologia I, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi – sequence: 13 givenname: Carmen surname: Morinelli fullname: Morinelli, Carmen organization: SOD Neurologia I, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi – sequence: 14 givenname: Antonella surname: Notarelli fullname: Notarelli, Antonella organization: Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi, SOD Neurologia I, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi – sequence: 15 givenname: Sandro surname: Sorbi fullname: Sorbi, Sandro organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, IRCCS Fondazione Don Carlo Gnocchi – sequence: 16 givenname: Benedetta surname: Nacmias fullname: Nacmias, Benedetta email: benedetta.nacmias@unifi.it organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, IRCCS Fondazione Don Carlo Gnocchi – sequence: 17 givenname: Valentina surname: Bessi fullname: Bessi, Valentina organization: Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38760423$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9u1DAQxiNUREvpC3BAlrhwCfhPnNgnhLYUViriAJwtJ5nseuXYwXYq7cvxbHg3S2k5ECXK2PP55xn7e16cOe-gKF4S_JZgJt7FinApSkyrsiY152X9pLiguOIlZZSePYjPi6sYdzg_nMqKyGfFORNNjSvKLopfN3OaA6AJQpygS-YOkHY96qxxptMW6WmyOWiNNWmP_IDSFlDnx9Y46NEc4TA3WR1Hjaatj_kLe6tTTiY9IyLIkedgDn4wVo_gErJms02o22rjUH6_ze3utPfKb5w5RtdwqGGp5oux_YPUepy0CQfSi-LpoG2Eq9P_svhx8_H76nN5-_XTevXhtuwqSVPJqRBskLgFVtXAKCYda6phwJIAlq2QAgbZ5nFPGkFxzwiRnEDTNFhjIjC7LNYLt_d6p6ZgRh32ymujjhM-bJQOyXQWFOUtH7SkA8030MhWDi3hvWDAoceay8x6v7CmuR2h73IbQdtH0McZZ7Zq4-8UIQTnq64y4c2JEPzPGWJSo4kdWKsd-Dkqhnld11JQmqWv_5Hu_BxcPqujCje4xof26KLqgo8xwHBfDcHqYDe12E1lu6mj3VSdF7162Mf9kj_mygK2CGJOuQ2Ev3v_B_sbeTbkrQ |
| Cites_doi | 10.1111/ene.16089 10.1016/j.jns.2023.120805 10.1136/jnnp-2022-329124 10.1136/jnnp-2018-320106 10.1002/acn3.50873 10.1038/s41380-020-00923-z 10.1038/s41591-020-0755-1 10.1038/nbt.1641 10.1038/nature12481 10.1001/jama.2009.1064 10.1016/j.jalz.2011.03.008 10.1016/j.jalz.2014.01.001 10.1111/cns.13962 10.1038/s43587-022-00269-x 10.1016/S1474-4422(21)00361-6 10.1093/brain/awaa399 10.1038/s41398-021-01709-9 10.1016/j.jalz.2011.03.003 10.1016/S1474-4422(18)30029-2 10.1016/j.jalz.2018.02.018 10.1016/S1474-4422(20)30314-8 10.1007/s00415-022-11055-5 10.1186/s12883-023-03347-8 10.1007/s10072-023-07065-4 10.1212/WNL.0000000000200035 10.1186/s13195-018-0398-3 10.2967/jnumed.119.236224 10.1007/s00401-020-02195-x 10.1093/braincomms/fcab045 10.1016/S0197-4580(03)00086-1 10.1212/WNL.0000000000201597 10.1093/brain/awac333 10.1001/jamaneurol.2022.5272 10.1111/ene.14518 10.1016/S1474-4422(12)70142-4 10.1212/WNL.0000000000200752 10.1212/WNL.0000000000009724 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PIMPY PQEST PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-024-61655-6 |
| DatabaseName | SpringerOpen Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Science Journals Biological Science Database Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_25b5fa92f220479b9fb15d83e5ed0a59 10_1038_s41598_024_61655_6 38760423 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Regione Toscana grantid: D19G22000640002 |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ADBBV ADRAZ AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7XB 8FK K9. M48 PQEST PQUKI Q9U 7X8 5PM AFPKN |
| ID | FETCH-LOGICAL-c492t-52883f90be346e3201c374ff091e09b898ef9bff0d17820d311951e7770a01803 |
| IEDL.DBID | RPM |
| ISSN | 2045-2322 |
| IngestDate | Tue Oct 22 14:43:19 EDT 2024 Tue Sep 17 21:28:45 EDT 2024 Sat Oct 26 04:30:39 EDT 2024 Sun Nov 17 06:12:00 EST 2024 Thu Nov 21 22:05:45 EST 2024 Sat Nov 02 12:25:38 EDT 2024 Fri Oct 11 20:56:18 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Alzheimer’s Disease p-tau181 Mild Cognitive Impairment Plasma biomarkers NfL Subjective Cognitive Decline |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c492t-52883f90be346e3201c374ff091e09b898ef9bff0d17820d311951e7770a01803 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101654/ |
| PMID | 38760423 |
| PQID | 3056070600 |
| PQPubID | 2041939 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_25b5fa92f220479b9fb15d83e5ed0a59 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11101654 proquest_miscellaneous_3056669822 proquest_journals_3056070600 crossref_primary_10_1038_s41598_024_61655_6 pubmed_primary_38760423 springer_journals_10_1038_s41598_024_61655_6 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-17 |
| PublicationDateYYYYMMDD | 2024-05-17 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2024 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Gaetani, Blennow, Calabresi, Di Filippo, Parnetti, Zetterberg (CR28) 2019; 90 Ebenau, Pelkmans, Verberk (CR14) 2022; 98 Mueller, Bullich, Barret (CR5) 2020; 61 Moscoso, Grothe, Ashton (CR10) 2021; 144 Mazzeo, Ingannato, Giacomucci (CR12) 2023 Mattsson-Carlgren, Salvadó, Ashton (CR32) 2023; 80 Chételat, Arbizu, Barthel (CR33) 2020; 19 Sperling, Aisen, Beckett (CR2) 2011; 7 Mazzeo, Lassi, Padiglioni (CR18) 2023; 23 Hampel, Au, Mattke (CR37) 2022; 2 Lewczuk, Esselmann, Otto (CR3) 2004; 25 Rissin, Kan, Campbell (CR22) 2010; 28 Mattsson, Zetterberg, Hansson (CR6) 2009; 302 Giacomucci, Mazzeo, Crucitti (CR11) 2023; 453 Karikari, Benedet, Ashton (CR23) 2021; 26 Giacomucci, Mazzeo, Bagnoli (CR20) 2022 Sarto, Ruiz-García, Guillén (CR30) 2023; 100 Perra, Bongianni, Novi (CR34) 2021; 3 Huang, Li, Xie, Guo (CR27) 2022; 28 Jessen, Amariglio, van Boxtel (CR17) 2014; 10 Dubois, Epelbaum, Nyasse (CR36) 2018; 17 Bessi, Giacomucci, Mazzeo (CR21) 2021; 28 Ebenau, Timmers, Wesselman (CR7) 2020; 95 Mazzeo, Ingannato, Giacomucci (CR13) 2023 Alcolea, Pegueroles, Muñoz (CR19) 2019; 6 Barba, Abu Rumeileh, Bellomo (CR26) 2023; 94 Shen, Huang, Chen (CR25) 2021; 11 Jack, Bennett, Blennow (CR1) 2018; 14 Clark, Pontecorvo, Beach (CR4) 2012; 11 Jucker, Walker (CR15) 2013; 501 Gaetani, Parnetti (CR29) 2022; 98 Janelidze, Bali, Ashton (CR31) 2023; 146 Janelidze, Mattsson, Palmqvist (CR24) 2020; 26 de Wilde, van Buchem, Otten (CR35) 2018; 10 Teunissen, Verberk, Thijssen (CR8) 2022; 21 Albert, DeKosky, Dickson (CR16) 2011; 7 Lantero Rodriguez, Karikari, Suárez-Calvet (CR9) 2020; 140 P Lewczuk (61655_CR3) 2004; 25 S Mazzeo (61655_CR12) 2023 L Barba (61655_CR26) 2023; 94 CM Clark (61655_CR4) 2012; 11 J Lantero Rodriguez (61655_CR9) 2020; 140 J Sarto (61655_CR30) 2023; 100 F Jessen (61655_CR17) 2014; 10 L Gaetani (61655_CR28) 2019; 90 JL Ebenau (61655_CR7) 2020; 95 G Giacomucci (61655_CR11) 2023; 453 V Bessi (61655_CR21) 2021; 28 CR Jack (61655_CR1) 2018; 14 S Janelidze (61655_CR24) 2020; 26 DM Rissin (61655_CR22) 2010; 28 D Perra (61655_CR34) 2021; 3 D Alcolea (61655_CR19) 2019; 6 MS Albert (61655_CR16) 2011; 7 S Mazzeo (61655_CR13) 2023 XN Shen (61655_CR25) 2021; 11 G Giacomucci (61655_CR20) 2022 A Mueller (61655_CR5) 2020; 61 H Hampel (61655_CR37) 2022; 2 G Chételat (61655_CR33) 2020; 19 M Jucker (61655_CR15) 2013; 501 RA Sperling (61655_CR2) 2011; 7 S Janelidze (61655_CR31) 2023; 146 N Mattsson (61655_CR6) 2009; 302 TK Karikari (61655_CR23) 2021; 26 B Dubois (61655_CR36) 2018; 17 A Moscoso (61655_CR10) 2021; 144 S Mazzeo (61655_CR18) 2023; 23 Y Huang (61655_CR27) 2022; 28 JL Ebenau (61655_CR14) 2022; 98 N Mattsson-Carlgren (61655_CR32) 2023; 80 A de Wilde (61655_CR35) 2018; 10 CE Teunissen (61655_CR8) 2022; 21 L Gaetani (61655_CR29) 2022; 98 |
| References_xml | – year: 2023 ident: CR12 article-title: Plasma neurofilament light chain predicts Alzheimer’s disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study publication-title: Eur. J. Neurol. doi: 10.1111/ene.16089 contributor: fullname: Giacomucci – volume: 453 start-page: 120805 year: 2023 ident: CR11 article-title: Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer’s disease pathology in subjective cognitive decline and mild cognitive impairment publication-title: J. Neurol. Sci. doi: 10.1016/j.jns.2023.120805 contributor: fullname: Crucitti – volume: 94 start-page: 83 issue: 1 year: 2023 end-page: 86 ident: CR26 article-title: Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease publication-title: J. Neurol. Neurosurg. Psychiatr. doi: 10.1136/jnnp-2022-329124 contributor: fullname: Bellomo – volume: 90 start-page: 870 issue: 8 year: 2019 end-page: 881 ident: CR28 article-title: Neurofilament light chain as a biomarker in neurological disorders publication-title: J. Neurol. Neurosurg. Psychiatr. doi: 10.1136/jnnp-2018-320106 contributor: fullname: Zetterberg – volume: 6 start-page: 1815 issue: 9 year: 2019 end-page: 1824 ident: CR19 article-title: Agreement of amyloid PET and CSF biomarkers for Alzheimer’s disease on lumipulse-pubmed publication-title: Ann. Clin. Transl. Neurol. doi: 10.1002/acn3.50873 contributor: fullname: Muñoz – volume: 26 start-page: 429 issue: 2 year: 2021 end-page: 442 ident: CR23 article-title: Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative publication-title: Mol. Psychiatr. doi: 10.1038/s41380-020-00923-z contributor: fullname: Ashton – volume: 26 start-page: 379 issue: 3 year: 2020 end-page: 386 ident: CR24 article-title: Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia publication-title: Nat. Med. doi: 10.1038/s41591-020-0755-1 contributor: fullname: Palmqvist – volume: 28 start-page: 595 issue: 6 year: 2010 end-page: 599 ident: CR22 article-title: Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations publication-title: Nat. Biotechnol. doi: 10.1038/nbt.1641 contributor: fullname: Campbell – volume: 501 start-page: 45 issue: 7465 year: 2013 end-page: 51 ident: CR15 article-title: Self-propagation of pathogenic protein aggregates in neurodegenerative diseases publication-title: Nature doi: 10.1038/nature12481 contributor: fullname: Walker – volume: 302 start-page: 385 issue: 4 year: 2009 end-page: 393 ident: CR6 article-title: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment publication-title: JAMA doi: 10.1001/jama.2009.1064 contributor: fullname: Hansson – volume: 7 start-page: 270 issue: 3 year: 2011 end-page: 279 ident: CR16 article-title: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease publication-title: Alz. Dement. doi: 10.1016/j.jalz.2011.03.008 contributor: fullname: Dickson – volume: 10 start-page: 844 issue: 6 year: 2014 end-page: 852 ident: CR17 article-title: A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease publication-title: Alz. Dement. doi: 10.1016/j.jalz.2014.01.001 contributor: fullname: van Boxtel – volume: 28 start-page: 2195 issue: 12 year: 2022 end-page: 2205 ident: CR27 article-title: Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients publication-title: CNS Neurosci. Ther. doi: 10.1111/cns.13962 contributor: fullname: Guo – volume: 2 start-page: 692 issue: 8 year: 2022 end-page: 703 ident: CR37 article-title: Designing the next-generation clinical care pathway for Alzheimer’s disease publication-title: Nat. Aging doi: 10.1038/s43587-022-00269-x contributor: fullname: Mattke – volume: 21 start-page: 66 issue: 1 year: 2022 end-page: 77 ident: CR8 article-title: Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(21)00361-6 contributor: fullname: Thijssen – volume: 144 start-page: 325 issue: 1 year: 2021 end-page: 339 ident: CR10 article-title: Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum publication-title: Brain doi: 10.1093/brain/awaa399 contributor: fullname: Ashton – volume: 11 start-page: 585 issue: 1 year: 2021 ident: CR25 article-title: Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status publication-title: Transl. Psychiatr. doi: 10.1038/s41398-021-01709-9 contributor: fullname: Chen – volume: 7 start-page: 280 issue: 3 year: 2011 end-page: 292 ident: CR2 article-title: Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease publication-title: Alz. Dement. doi: 10.1016/j.jalz.2011.03.003 contributor: fullname: Beckett – volume: 17 start-page: 335 issue: 4 year: 2018 end-page: 346 ident: CR36 article-title: Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): A longitudinal observational study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30029-2 contributor: fullname: Nyasse – volume: 14 start-page: 535 issue: 4 year: 2018 end-page: 562 ident: CR1 article-title: NIA-AA research framework: Toward a biological definition of Alzheimer’s disease publication-title: Alz. Dement. doi: 10.1016/j.jalz.2018.02.018 contributor: fullname: Blennow – volume: 19 start-page: 951 issue: 11 year: 2020 end-page: 962 ident: CR33 article-title: Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(20)30314-8 contributor: fullname: Barthel – year: 2022 ident: CR20 article-title: Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in subjective cognitive decline and mild cognitive impairment publication-title: J. Neurol. doi: 10.1007/s00415-022-11055-5 contributor: fullname: Bagnoli – volume: 23 start-page: 1 year: 2023 ident: CR18 article-title: Predicting the evolution of subjective cognitive decline to Alzheimer’s disease with machine learning: The preview study protocol publication-title: BMC Neurol. doi: 10.1186/s12883-023-03347-8 contributor: fullname: Padiglioni – year: 2023 ident: CR13 article-title: The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment publication-title: Neurol. Sci. doi: 10.1007/s10072-023-07065-4 contributor: fullname: Giacomucci – volume: 98 start-page: e1315 issue: 13 year: 2022 end-page: e1326 ident: CR14 article-title: Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline publication-title: Neurology doi: 10.1212/WNL.0000000000200035 contributor: fullname: Verberk – volume: 10 start-page: 72 issue: 1 year: 2018 ident: CR35 article-title: Disclosure of amyloid positron emission tomography results to individuals without dementia: A systematic review publication-title: Alz. Res. Ther. doi: 10.1186/s13195-018-0398-3 contributor: fullname: Otten – volume: 61 start-page: 911 issue: 6 year: 2020 end-page: 919 ident: CR5 article-title: Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: A first-in-humans study publication-title: J. Nucl. Med. doi: 10.2967/jnumed.119.236224 contributor: fullname: Barret – volume: 140 start-page: 267 issue: 3 year: 2020 end-page: 278 ident: CR9 article-title: Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline publication-title: Acta Neuropathol. doi: 10.1007/s00401-020-02195-x contributor: fullname: Suárez-Calvet – volume: 3 start-page: fcab045 issue: 2 year: 2021 ident: CR34 article-title: Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with lewy bodies publication-title: Brain Commun. doi: 10.1093/braincomms/fcab045 contributor: fullname: Novi – volume: 25 start-page: 273 issue: 3 year: 2004 end-page: 281 ident: CR3 article-title: Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau publication-title: Neurobiol. Aging doi: 10.1016/S0197-4580(03)00086-1 contributor: fullname: Otto – volume: 100 start-page: e860 issue: 8 year: 2023 end-page: e873 ident: CR30 article-title: Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort publication-title: Neurology doi: 10.1212/WNL.0000000000201597 contributor: fullname: Guillén – volume: 146 start-page: 1592 issue: 4 year: 2023 end-page: 1601 ident: CR31 article-title: Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease publication-title: Brain doi: 10.1093/brain/awac333 contributor: fullname: Ashton – volume: 80 start-page: 360 issue: 4 year: 2023 end-page: 369 ident: CR32 article-title: Prediction of longitudinal cognitive decline in preclinical alzheimer disease using plasma biomarkers publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2022.5272 contributor: fullname: Ashton – volume: 28 start-page: 56 issue: 1 year: 2021 end-page: 65 ident: CR21 article-title: PER2 C111G polymorphism, cognitive reserve and cognition in subjective cognitive decline and mild cognitive impairment: A 10-year follow-up study publication-title: Eur. J. Neurol. doi: 10.1111/ene.14518 contributor: fullname: Mazzeo – volume: 11 start-page: 669 issue: 8 year: 2012 end-page: 678 ident: CR4 article-title: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(12)70142-4 contributor: fullname: Beach – volume: 98 start-page: 911 issue: 22 year: 2022 end-page: 912 ident: CR29 article-title: NfL as analogue of C-reactive protein in neurologic diseases: Instructions for use publication-title: Neurology doi: 10.1212/WNL.0000000000200752 contributor: fullname: Parnetti – volume: 95 start-page: e46 issue: 1 year: 2020 end-page: e58 ident: CR7 article-title: ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project publication-title: Neurology doi: 10.1212/WNL.0000000000009724 contributor: fullname: Wesselman – volume: 144 start-page: 325 issue: 1 year: 2021 ident: 61655_CR10 publication-title: Brain doi: 10.1093/brain/awaa399 contributor: fullname: A Moscoso – volume: 11 start-page: 585 issue: 1 year: 2021 ident: 61655_CR25 publication-title: Transl. Psychiatr. doi: 10.1038/s41398-021-01709-9 contributor: fullname: XN Shen – volume: 2 start-page: 692 issue: 8 year: 2022 ident: 61655_CR37 publication-title: Nat. Aging doi: 10.1038/s43587-022-00269-x contributor: fullname: H Hampel – volume: 23 start-page: 1 year: 2023 ident: 61655_CR18 publication-title: BMC Neurol. doi: 10.1186/s12883-023-03347-8 contributor: fullname: S Mazzeo – volume: 6 start-page: 1815 issue: 9 year: 2019 ident: 61655_CR19 publication-title: Ann. Clin. Transl. Neurol. doi: 10.1002/acn3.50873 contributor: fullname: D Alcolea – volume: 94 start-page: 83 issue: 1 year: 2023 ident: 61655_CR26 publication-title: J. Neurol. Neurosurg. Psychiatr. doi: 10.1136/jnnp-2022-329124 contributor: fullname: L Barba – volume: 95 start-page: e46 issue: 1 year: 2020 ident: 61655_CR7 publication-title: Neurology doi: 10.1212/WNL.0000000000009724 contributor: fullname: JL Ebenau – volume: 90 start-page: 870 issue: 8 year: 2019 ident: 61655_CR28 publication-title: J. Neurol. Neurosurg. Psychiatr. doi: 10.1136/jnnp-2018-320106 contributor: fullname: L Gaetani – volume: 25 start-page: 273 issue: 3 year: 2004 ident: 61655_CR3 publication-title: Neurobiol. Aging doi: 10.1016/S0197-4580(03)00086-1 contributor: fullname: P Lewczuk – volume: 10 start-page: 844 issue: 6 year: 2014 ident: 61655_CR17 publication-title: Alz. Dement. doi: 10.1016/j.jalz.2014.01.001 contributor: fullname: F Jessen – volume: 98 start-page: e1315 issue: 13 year: 2022 ident: 61655_CR14 publication-title: Neurology doi: 10.1212/WNL.0000000000200035 contributor: fullname: JL Ebenau – volume: 501 start-page: 45 issue: 7465 year: 2013 ident: 61655_CR15 publication-title: Nature doi: 10.1038/nature12481 contributor: fullname: M Jucker – volume: 10 start-page: 72 issue: 1 year: 2018 ident: 61655_CR35 publication-title: Alz. Res. Ther. doi: 10.1186/s13195-018-0398-3 contributor: fullname: A de Wilde – volume: 26 start-page: 379 issue: 3 year: 2020 ident: 61655_CR24 publication-title: Nat. Med. doi: 10.1038/s41591-020-0755-1 contributor: fullname: S Janelidze – volume: 17 start-page: 335 issue: 4 year: 2018 ident: 61655_CR36 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30029-2 contributor: fullname: B Dubois – volume: 7 start-page: 270 issue: 3 year: 2011 ident: 61655_CR16 publication-title: Alz. Dement. doi: 10.1016/j.jalz.2011.03.008 contributor: fullname: MS Albert – volume: 453 start-page: 120805 year: 2023 ident: 61655_CR11 publication-title: J. Neurol. Sci. doi: 10.1016/j.jns.2023.120805 contributor: fullname: G Giacomucci – volume: 61 start-page: 911 issue: 6 year: 2020 ident: 61655_CR5 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.119.236224 contributor: fullname: A Mueller – volume: 140 start-page: 267 issue: 3 year: 2020 ident: 61655_CR9 publication-title: Acta Neuropathol. doi: 10.1007/s00401-020-02195-x contributor: fullname: J Lantero Rodriguez – volume: 14 start-page: 535 issue: 4 year: 2018 ident: 61655_CR1 publication-title: Alz. Dement. doi: 10.1016/j.jalz.2018.02.018 contributor: fullname: CR Jack – volume: 7 start-page: 280 issue: 3 year: 2011 ident: 61655_CR2 publication-title: Alz. Dement. doi: 10.1016/j.jalz.2011.03.003 contributor: fullname: RA Sperling – volume: 302 start-page: 385 issue: 4 year: 2009 ident: 61655_CR6 publication-title: JAMA doi: 10.1001/jama.2009.1064 contributor: fullname: N Mattsson – year: 2022 ident: 61655_CR20 publication-title: J. Neurol. doi: 10.1007/s00415-022-11055-5 contributor: fullname: G Giacomucci – volume: 28 start-page: 595 issue: 6 year: 2010 ident: 61655_CR22 publication-title: Nat. Biotechnol. doi: 10.1038/nbt.1641 contributor: fullname: DM Rissin – volume: 3 start-page: fcab045 issue: 2 year: 2021 ident: 61655_CR34 publication-title: Brain Commun. doi: 10.1093/braincomms/fcab045 contributor: fullname: D Perra – year: 2023 ident: 61655_CR12 publication-title: Eur. J. Neurol. doi: 10.1111/ene.16089 contributor: fullname: S Mazzeo – volume: 11 start-page: 669 issue: 8 year: 2012 ident: 61655_CR4 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(12)70142-4 contributor: fullname: CM Clark – volume: 21 start-page: 66 issue: 1 year: 2022 ident: 61655_CR8 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(21)00361-6 contributor: fullname: CE Teunissen – volume: 28 start-page: 56 issue: 1 year: 2021 ident: 61655_CR21 publication-title: Eur. J. Neurol. doi: 10.1111/ene.14518 contributor: fullname: V Bessi – volume: 28 start-page: 2195 issue: 12 year: 2022 ident: 61655_CR27 publication-title: CNS Neurosci. Ther. doi: 10.1111/cns.13962 contributor: fullname: Y Huang – volume: 19 start-page: 951 issue: 11 year: 2020 ident: 61655_CR33 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(20)30314-8 contributor: fullname: G Chételat – volume: 100 start-page: e860 issue: 8 year: 2023 ident: 61655_CR30 publication-title: Neurology doi: 10.1212/WNL.0000000000201597 contributor: fullname: J Sarto – volume: 26 start-page: 429 issue: 2 year: 2021 ident: 61655_CR23 publication-title: Mol. Psychiatr. doi: 10.1038/s41380-020-00923-z contributor: fullname: TK Karikari – volume: 80 start-page: 360 issue: 4 year: 2023 ident: 61655_CR32 publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2022.5272 contributor: fullname: N Mattsson-Carlgren – year: 2023 ident: 61655_CR13 publication-title: Neurol. Sci. doi: 10.1007/s10072-023-07065-4 contributor: fullname: S Mazzeo – volume: 98 start-page: 911 issue: 22 year: 2022 ident: 61655_CR29 publication-title: Neurology doi: 10.1212/WNL.0000000000200752 contributor: fullname: L Gaetani – volume: 146 start-page: 1592 issue: 4 year: 2023 ident: 61655_CR31 publication-title: Brain doi: 10.1093/brain/awac333 contributor: fullname: S Janelidze |
| SSID | ssj0000529419 |
| Score | 2.4665127 |
| Snippet | We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD) and Mild... Abstract We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately and in combination in discriminating Subjective Cognitive Decline (SCD)... |
| SourceID | doaj pubmedcentral proquest crossref pubmed springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 11307 |
| SubjectTerms | 692/617 692/617/375/132 Accuracy Aged Alzheimer Disease - blood Alzheimer Disease - diagnosis Alzheimer's disease Amyloid beta-Peptides - blood Amyloid beta-Peptides - cerebrospinal fluid Biomarkers Biomarkers - blood Cerebrospinal fluid Cognitive ability Cognitive Dysfunction - blood Cognitive Dysfunction - diagnosis Female Humanities and Social Sciences Humans Male Middle Aged Mild Cognitive Impairment multidisciplinary Neurodegenerative diseases Neurofilament Proteins - blood NfL p-tau181 Pathology Phosphorylation Plasma Plasma biomarkers Science Science (multidisciplinary) Subjective Cognitive Decline Tau protein tau Proteins - blood tau Proteins - cerebrospinal fluid |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgJSQuiDdhF2QkbhBtaiexfYTdrZYDXACJm2XHthpU0qppDv1z_LadsZPuloe4ICWHxFEy8owz32hmPhPy2gEU8oaF3FpW5uBvVS6tK_MA8BTQtnfWYb_z5Wfx6Zs8v0CanP1WX1gTluiB08SdsspWwSgWGEM2dKuCnVVOcl95V5gqte4V9Y1gKrF6MwXfHbtkCi5Pe_BU2E0GEtWzuqry-sATRcL-P6HM34slf8mYRkc0v0_ujQiSvkuSPyC3fPeQ3El7Su4ekZ_zyBJC19ddlNR0jk4tkHRMWcei2B1dBQoQkILdQYjsHR16j_fWAKp_GLperHo4N7slQFJHt2ag4Kvj-yIRZmjBoEBiusQYnzYL03YUDvgdfR-_fTbVJ9FzjzIkaT62S3dj6AP8lNoNvukx-Tq_-HJ2mY-bNORNqdgWAlkpeVCF9bysPQc80XBRhgA4xBfKSiV9UBau3Qyp-RxHjrmZF0IUBsnD-BNy1K06_4zQsvKCl403hQLf6pQBMFIzIbhwDabvMvJmUpheJy4OHXPoXOqkXg3q1VG9us7Ie9Tp_knk0Y43wLr0aF36X9aVkZPJIvS4uHuNUVeBrENFRl7th2FZYq7FdH41pGfqGskRM_I0GdBeEg4eCMuRMiIPTOtA1MORrl1E6m_wTLH_LCNvJyu8luvvc_H8f8zFMbnLcPkgda04IUfbzeBfkNu9G17GxXcFCro0Hw priority: 102 providerName: Directory of Open Access Journals |
| Title | Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment |
| URI | https://link.springer.com/article/10.1038/s41598-024-61655-6 https://www.ncbi.nlm.nih.gov/pubmed/38760423 https://www.proquest.com/docview/3056070600 https://www.proquest.com/docview/3056669822 https://pubmed.ncbi.nlm.nih.gov/PMC11101654 https://doaj.org/article/25b5fa92f220479b9fb15d83e5ed0a59 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELboSkhcEMszsKyMxA2yTeMkto_Q3Wo5LEICJG6RHds0qzaJmubQP8dv2xkn6W55XJDaQ-M0HnVmPJ87M58JeWsAClkVu1DrOAkh3spQaJOEDuApoG1rtMF-58uv_PMPcX6BNDnZ2Avji_YLXZ5Vq_VZVS59bWWzLqZjndj0y9Uc_NN34UwnZALg8M4evWf0jiXMOXTIRExMW4hS2EkG0mTwvTTEg4sYrANYFHIQkDxv_9_A5p81k78lTn08WjwiDwcgST_0Ah-Te7Z6TO73R0vunpBfC08WQpvbZkqqKkPHTkg6ZK59beyO1o4CEqRgfrBTtoZ2rcVrDWDrtaLNsm7hvdmtAJkaulUdhZDtn-f5MF0JdgUS0xVu9WmxVGVF4QWr0vUw93wsU6LnFmXopbkqV-bO0CdYm8oNPukp-b64-Da_DIezGsIikfEW9rNCMCcjbVmSWQawomA8cQ7giI2kFlJYJzV8NjNk6DMMqeZmlnMeKeQQY8_IUVVX9gWhSWo5SwqrIgkh1kgFmCSLOWfcFJjFC8i7UWF501Ny5D6VzkTeazoHTede03kWkI-o0_2dSKftL9Sbn_lgVHmc6tQpGbs4Rsp9LZ2epUYwm1oTqVQG5GS0iHzw8TbHzVeE5ENRQN7sh8E7MeWiKlt3_T1ZhhyJAXneG9BektEAAyIOTOtA1MMRcAjPAD46QEDej1Z4K9e_f4uX_z_TK_IgRv9B3lp-Qo62m86-JpPWdKf-b4xT74M3CCo1tQ |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB6xixBceC8EFjASN8g2jfPyEbq76ortColF4mbZsU2D2rTq49A_x29jxkm6Wx6XldpD4zSeNJ89nzsznwHeGaRCVsUu1DpOQvS3Iiy0SUKH9BTZtjXaUL3z8Gt-8b04PiGZnKyrhfFJ-6WujurJ9Kiuxj63cj4te12eWO_LaIDj01fh9PbgNg7YKLq2Sm80vWOBvbY1MhEvekv0U1RLhvZk-M00pK2LOM4ElBay45K8cv-_6ObfWZN_hE69Rzp9cNN7eQj3Ww7KPjbtj-CWrR_DnWZXys0T-HXqdUbY_KoOk6nasK6IkrVBb59Wu2Ezx5BEMkQuLrKtYeulpWNzpOVTxebj2RLfi80ESa1hK7Vm6O399byUpqsQknirbEL_ErByrKqa4QsntJ9t34Muw4kdW7KhsWZUTcy1pjOc1qoFXekpfDs9uRwMw3abh7BMRLzCpXBRcCcibXmSWY6MpOR54hwyGRsJXYjCOqHxs-mTuJ_hpFLXt3meR4rkx_gB7Nez2j4HlqQ250lpVSTQOxuhkM5kcZ7z3JQUAAzgffek5bxR85A-Cs8L2UBEIkSkh4jMAvhEYNieSUrc_sBs8UO2z1DGqU6dErGLY1Lr18LpfmoKblNrIpWKAA47KMl2elhKWrdFpFsUBfB224wDm6I1qrazdXNOlpG8YgDPGuRtLemQG0Cxg8kdU3dbEH9ePLzDWwAfOvhe2fX_3-LFzXt6A3eHl6NzeX528fkl3ItpEJL8bX4I-6vF2r6CvaVZv_ZD-DcaV0ps |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYRSAuvBcCCxiJG2Sb2nmZG7Rb7Qp2tRIgcbPs2KZBbRq1zaF_jt_GjJN0tzwuILWHxk48ST57Ptcznwl5ZYAKWcVcqDWLQ_C3Isy1iUMH9BTYtjXaYL7zyafs_Gs-PkaZnLd9LowP2i90eVTN5kdVOfWxlfW8GPRxYoOLsxH0T5-FM6iNG-yR69BpI3Zlpt7qejMBLXd5MhHPByvwVZhPBjalcHYS4vZFHEYDDA3ZcUtevf9PlPP3yMlflk-9V5rc-Z_7uUtud1yUvmvr3CPXbHWf3Gh3p9w8ID8mXm-E1pf5mFRVhvbJlLRb_PbhtRu6cBTIJAUEw2TbGtqsLB6rgZ7PFa2nixV8l5sZkFtD16qh4PX99bykpisBmnC7dIb_FtBiqsqKwgcGtu9d26M-0omOLdrQWnNWzsyVolMY3solXukh-TI5_jw6CbvtHsIiFmwNU-I8505E2vI4tRyYScGz2DlgNDYSOhe5dULDbzNEkT_DUa1uaLMsixTKkPEDsl8tKvuY0DixGY8LqyIBXtoIBbQmZVnGM1PgQmBAXvdvW9atqof0q_E8ly1MJMBEepjINCDvERDbmqjI7Q8slt9k9x4lS3TilGCOMVTt18LpYWJybhNrIpWIgBz2cJLdMLGSOH-LUL8oCsjLbTF0cFy1UZVdNG2dNEWZxYA8atG3taRHb0DyHVzumLpbAhj0IuI95gLypofwpV1_fxZP_r2lF-TmxXgiP56ef3hKbjHsh6iCmx2S_fWysc_I3so0z30v_gloXkzs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Future+perspective+and+clinical+applicability+of+the+combined+use+of+plasma+phosphorylated+tau+181+and+neurofilament+light+chain+in+Subjective+Cognitive+Decline+and+Mild+Cognitive+Impairment&rft.jtitle=Scientific+reports&rft.au=Giacomucci%2C+Giulia&rft.au=Mazzeo%2C+Salvatore&rft.au=Ingannato%2C+Assunta&rft.au=Crucitti%2C+Chiara&rft.date=2024-05-17&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-024-61655-6&rft.externalDocID=10_1038_s41598_024_61655_6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |